Skip to main content
Terug
Watch Compare

ADIAL PHARMACEUTICALS, INC.

Datakwaliteit: 83%
ADIL
NASDAQ Manufacturing Chemicals
€ 1,57
▲ € 0,01 (0,64%)
Marktkapitalisatie: 2,23 M
Prijs
€ 1,56
Marktkapitalisatie
2,23 M
Dagbereik
—
52-Weeksbereik
—
Volume
—
Openen —
50D / 200D Gem.
—
50D / 200D Gem.
—

Quick Summary

Belangrijkste Punten

Negative free cash flow of -6,49 M

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-158,03%
Onder sectorgemiddelde (-54,44%)
ROIC-122,06%
Net MarginN/A
Op. MarginN/A

Veiligheid

Debt / Equity
N/A
Current Ratio4,34
Interest CoverageN/A

Waardering

PE (TTM|NTM)
-0,28 | -0,33
Boven sectorgemiddelde (-1,49)
P/B Ratio0,49
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1385 peers)
Metriek Aandeel Sector Mediaan
P/E -0,3 -1,5
P/B 0,5 1,6
ROE % -158,0 -54,4
Net Margin % — -41,5
Rev Growth 5Y % — 1,9
D/E — 0,3

Koersdoel Analisten

3 analisten
Buy
Huidig
€ 1,57
+1386.2%
Koersdoel
€ 23,33
€ 8,00
€ 20,00
€ 42,00
Vooruitzicht
Forward K/W -0,33
Forward WPA -€ 4,80
Omzet Sch. 0,0

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2027 -€ 4,80
-€ 7,00 – -€ 2,59
 0,0 2
FY2026 -€ 6,59
-€ 7,55 – -€ 4,89
 0,0 3

Winstverassingen

Laatste 4 kwartalen
Kwartaal Geschat WPA Werkelijk WPA Verrassing
Q42025 -€ 2,13 -€ 11,48 -439,0%
Q32025 -€ 3,50 -€ 2,00 +42,9%
Q22025 -€ 5,50 -€ 4,50 +18,2%
Q12025 -€ 12,38 -€ 8,50 +31,3%

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -7,98 M
ROE -158,03% ROA -128,03%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -6,49 M
ROIC -122,06% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 4,34
Interest Coverage N/A Asset Turnover N/A
Working Capital 3,86 M Tangible Book Value 4,50 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0,28 Forward P/E -0,33
P/B Ratio 0,49 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -291,46%
Market Cap 2,23 M Enterprise Value -2,38 M
Per Share
EPS (Diluted TTM) -11,93 Revenue / Share N/A
FCF / Share -4,55 OCF / Share -4,55
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 81,39%
SBC-Adj. FCF -7,43 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue — — — — —
Net Income -7,98 M -13,20 M -5,12 M -12,73 M -19,42 M
EPS (Diluted) -11,93 -2,72 -3,60 -0,51 —
Gross Profit — — — — —
Operating Income -7,80 M -8,28 M -6,89 M -13,32 M -19,29 M
EBITDA — — — — —
R&D Expenses 2,62 M 3,23 M 1,27 M 4,18 M 8,40 M
SG&A Expenses — — — — —
D&A — — — — —
Interest Expense — — — — —
Income Tax — — — -502,0 -94.077,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 6,67 M 5,04 M 4,74 M 5,73 M 7,47 M
Total Liabilities 1,40 M 975.858,0 653.076,0 2,46 M 3,97 M
Shareholders' Equity 5,28 M 4,07 M 4,08 M 3,28 M 3,51 M
Total Debt — — — — —
Cash & Equivalents 5,88 M 3,75 M 2,83 M 4,00 M 6,06 M
Current Assets 6,18 M 4,06 M 3,20 M 4,78 M 6,46 M
Current Liabilities 1,40 M 975.858,0 653.076,0 1,79 M 2,72 M